What Is Positron Emission Tomography?

Positron emission tomography (PET) is a nuclear medicine imaging technique that produces quantitative, three-dimensional maps of metabolic and biochemical activity within living tissue. The technique relies on the annihilation physics of positrons: a patient is administered a radiopharmaceutical that emits positrons as it decays, and a ring of detectors surrounding the patient records the paired 511 keV gamma rays produced when those positrons encounter electrons in tissue. By measuring the coincident arrival of photon pairs from many angles, a reconstruction algorithm assembles a volumetric image that reflects where the radiopharmaceutical has concentrated. Because PET images metabolic function rather than anatomical structure, it detects pathological changes that precede visible structural abnormalities on conventional scans.

PET draws its theoretical and physical foundations from nuclear physics, radiation detection engineering, and signal processing. Its development accelerated in the 1970s at research centers including Massachusetts General Hospital and Washington University in St. Louis, as cyclotron production of short-lived positron-emitting isotopes became practical alongside advances in coincidence detector circuits.

Radiopharmaceuticals and Radionuclides

The choice of positron-emitting isotope determines what biological process the scan images. The dominant agent in clinical practice is 2-[18F]fluoro-2-deoxy-D-glucose (FDG), a glucose analogue labeled with fluorine-18. Because tumor cells consume glucose at elevated rates relative to surrounding tissue, FDG accumulates preferentially in malignant lesions, making it effective for cancer staging and treatment monitoring. Fluorine-18 has a half-life of approximately 110 minutes, long enough to allow synthesis and transport from a regional cyclotron. Other radionuclides used in specific protocols include carbon-11 (half-life 20 minutes), nitrogen-13, oxygen-15, and gallium-68, each selected to label molecules that probe particular physiological pathways. NIH reviews of nuclear medicine imaging describe how the short half-lives of these isotopes minimize radiation dose to the patient while allowing metabolic snapshots on clinically useful timescales.

Detector Technology and System Design

Modern PET scanners use rings of scintillator crystals coupled to photodetectors. Lutetium oxyorthosilicate (LSO) and its variants have largely replaced the earlier bismuth germanate (BGO) crystals because LSO offers higher light output and shorter decay times, improving both spatial resolution and count-rate performance. The fundamental measurement is coincidence detection: two photons registered within a narrow time window, typically a few nanoseconds, are presumed to originate from the same annihilation event and define a line of response through the patient. Iterative reconstruction algorithms, such as ordered-subset expectation maximization (OSEM), convert the measured line-of-response data into calibrated images of radiotracer concentration. Phantom studies, in which standardized test objects with known activity concentrations are scanned, provide the reference measurements needed to validate system resolution, sensitivity, and quantitative accuracy across installations. The comprehensive overview published in PMC details the progression from early single-ring scanners to the multi-ring, fully three-dimensional systems now standard in clinical practice.

Multimodality Imaging

Standalone PET images lack anatomical reference, making lesion localization difficult. PET/CT systems, which acquired commercial significance after their introduction in the late 1990s, acquire PET emission data and CT attenuation data in a single scanning session, producing fused images that overlay metabolic activity on anatomical structure. PET/MR systems, introduced for clinical use around 2010, combine the superior soft-tissue contrast of magnetic resonance imaging with the functional sensitivity of PET, particularly valuable in brain and prostate imaging. Fusing these modalities requires simultaneous or near-simultaneous acquisition along with careful software registration to correct for patient motion between scans. According to studies on PET instrumentation innovations, whole-body PET/MR systems present significant engineering challenges in detector design, because conventional photomultiplier tubes cannot operate within a strong magnetic field, driving adoption of silicon photomultipliers that are MR-compatible.

Applications

Positron emission tomography has applications across a wide range of medical disciplines, including:

• Oncology: staging, treatment response assessment, and recurrence detection in lung, breast, colorectal, and lymphatic cancers
• Neurology: diagnosis and progression monitoring in Alzheimer's disease, epilepsy localization, and brain tumor delineation
• Cardiology: assessment of myocardial viability and blood flow in ischemic heart disease
• Radiotherapy planning: tumor volume delineation for radiation dose delivery
• Drug development: tracing receptor occupancy and pharmacokinetic behavior of new therapeutic compounds